Telesis Bio, Inc. Stock

Equities

TBIO

US1920031010

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 16:30:00 2024-04-26 EDT 5-day change 1st Jan Change
0.3184 USD -0.93% Intraday chart for Telesis Bio, Inc. +3.04% -20.20%
Sales 2024 * 35.5M 48.52M Sales 2025 * 46.5M 63.56M Capitalization 9.58M 13.1M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 0.27 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.21 x
P/E ratio 2024 *
-0.41 x
P/E ratio 2025 *
-0.55 x
Employees 142
Yield 2024 *
-
Yield 2025 *
-
Free-Float 62.32%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.93%
1 week+3.04%
Current month-27.64%
1 month-29.24%
3 months-6.35%
6 months-56.97%
Current year-20.20%
More quotes
1 week
0.30
Extreme 0.2997
0.35
1 month
0.30
Extreme 0.2997
0.48
Current year
0.30
Extreme 0.2997
0.86
1 year
0.30
Extreme 0.2997
3.01
3 years
0.30
Extreme 0.2997
25.70
5 years
0.30
Extreme 0.2997
25.70
10 years
0.30
Extreme 0.2997
25.70
More quotes
Managers TitleAgeSince
Founder 47 11-03-23
Chief Executive Officer 54 22-04-30
Director of Finance/CFO 64 23-08-27
Members of the board TitleAgeSince
Director/Board Member 65 21-05-31
Director/Board Member 65 21-04-30
Director/Board Member 58 23-10-17
More insiders
Date Price Change Volume
24-04-26 0.3184 -0.93% 26,538
24-04-25 0.3214 +0.03% 26,908
24-04-24 0.3213 -0.68% 127,758
24-04-23 0.3235 +2.63% 140,339
24-04-22 0.3152 +2.01% 70,346

Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm

More quotes
Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3184
Average target price
-
Consensus